- Home
- COLL vs AIV Comparison
COLL vs AIV Comparison
Compare COLL & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- AIV
- Stock Information
- Founded
- COLL 2002
- AIV 1975
- Country
- COLL United States
- AIV United States
- Employees
- COLL N/A
- AIV N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- AIV Real Estate Investment Trusts
- Sector
- COLL Health Care
- AIV Real Estate
- Exchange
- COLL Nasdaq
- AIV Nasdaq
- Market Cap
- COLL 1.1B
- AIV 1.2B
- IPO Year
- COLL 2015
- AIV 1994
- Fundamental
- Price
- COLL $29.58
- AIV $8.62
- Analyst Decision
- COLL Strong Buy
- AIV
- Analyst Count
- COLL 6
- AIV 0
- Target Price
- COLL $42.00
- AIV N/A
- AVG Volume (30 Days)
- COLL 440.1K
- AIV 974.5K
- Earning Date
- COLL 11-07-2024
- AIV 11-07-2024
- Dividend Yield
- COLL N/A
- AIV N/A
- EPS Growth
- COLL 757.11
- AIV N/A
- EPS
- COLL 2.16
- AIV N/A
- Revenue
- COLL $599,245,000.00
- AIV $204,735,000.00
- Revenue This Year
- COLL $13.02
- AIV N/A
- Revenue Next Year
- COLL $18.01
- AIV $6.56
- P/E Ratio
- COLL $13.68
- AIV N/A
- Revenue Growth
- COLL 9.62
- AIV 13.91
- 52 Week Low
- COLL $25.07
- AIV $6.49
- 52 Week High
- COLL $42.29
- AIV $9.49
- Technical
- Relative Strength Index (RSI)
- COLL 26.96
- AIV 49.25
- Support Level
- COLL $29.69
- AIV $8.40
- Resistance Level
- COLL $35.62
- AIV $8.81
- Average True Range (ATR)
- COLL 1.41
- AIV 0.23
- MACD
- COLL -0.39
- AIV 0.02
- Stochastic Oscillator
- COLL 6.36
- AIV 67.50
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About AIV Apartment Investment and Management Company
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. The company generates majority of revenue from operating segment.